Core Viewpoint - Huarun Pharmaceutical announced that its chairman, Zhang Li, has been placed under residential surveillance by the local police, which is unrelated to the company or its operations. Zhang has submitted his resignation from all positions within the company due to personal reasons [1][4]. Company Management Changes - The board of Huarun Pharmaceutical held a meeting on August 24, 2023, and appointed director Hou Ruipeng to act as chairman and legal representative temporarily. The company will expedite the process of electing a new chairman according to legal procedures [4]. - Zhang Li was elected as the new chairman on April 29, 2023, and his tenure lasted less than four months before the surveillance incident [4][5]. Financial Performance - Huarun Pharmaceutical reported a significant financial downturn in its 2024 annual report, with revenue of 1.353 billion yuan, a year-on-year decrease of 17.3%. The net profit attributable to shareholders was a loss of 1.368 billion yuan, a staggering decline of 827.67% [11]. - The company attributed the massive loss primarily to a full provision for credit impairment losses related to 1.3478 billion yuan owed to China National Pharmaceutical Group [11]. - The company also reported a decline in its 2025 semi-annual results, with revenue of 624 million yuan, down 19.13%, and a net profit of 37.33 million yuan, down 49.01% [12]. Stock Market Performance - As of August 26, 2023, Huarun Pharmaceutical's stock closed at 3.63 yuan per share, with a total market capitalization of 4.291 billion yuan [13].
300110,董事长被监视居住